Oruka Therapeutics, Inc. cash flow to debt ratio of -4.57K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Oruka Therapeutics, Inc.'s free cash flow has decreased 52.38% from $-58.03M last year to $-88.42M, signaling decreasing performance

Oruka Therapeutics, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Oruka Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.00 last year to 0.00 today, signaling strengthened financials

Oruka Therapeutics, Inc. has a net cash position, so leverage is healthy.

Oruka Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Oruka Therapeutics, Inc. has insufficient data to evaluate this check.

Oruka Therapeutics, Inc.'s short-term assets of $343.86M exceed its short-term liabilities of $15.37M

Oruka Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Oruka Therapeutics, Inc.'s return on equity of -25.99%, is lower than 15.00%, indicating bad performance

Oruka Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Oruka Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Oruka Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Oruka Therapeutics, Inc. has negative free cash flow, indicating cash burn

Oruka Therapeutics, Inc.'s yearly earnings has decreased 25.93% since last year from $-83.72M to $-105.43M, signaling decreasing performance

Oruka Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -27.31% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Oruka Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Oruka Therapeutics, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Oruka Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Oruka Therapeutics, Inc. has insufficient data to evaluate this check.

Oruka Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Oruka Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Oruka Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Oruka Therapeutics, Inc. has insufficient data to evaluate this check.

Oruka Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Oruka Therapeutics, Inc. has a price-to-book ratio of 11.92x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Oruka Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue